I did take the time to quickly read one article, which compared PCLO to another pot stock. I agree 100% with the conclusion, which was as follows:
Conclusion: I am not knocking PCLO but I am saying as an investor, KHRN seems a far more attractive opportunity. Assuming both companies are successful, I want to end up where KHRN is going far more than where PCLO is headed. I would rather end up as the L'Oréal, Unilever or Proctor and Gamble of the cannabis cosmeceutical world. Perhaps the most important consideration from an investment point of view is that Khiron trades at approximately one-third of the market cap of PharmaCielo. So if you offer me all the advantages I see in KHRN’s business plan and the team of people they have assembled to carry out their plan under the leadership of Alvaro Torres, Chief Executive Officer and Chris Naprawa, President and I can have it all for around one-third of the valuation I have to prefer KHRN in a portfolio. If you own both, I suggest KHRN should be the much larger holding.
Ouch.
Add to My Watchlist
What is My Watchlist?